GlassScriptPhysician profile
Amy Fowler
NPI 1801051891
$7,520.93
in general payments reported to CMS, 2019-2025
43 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $994 · 2021: $1,180 · 2022: $2,621 · 2023: $914 · 2024: $661 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,030 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,030.35 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,084.82 | 2022 | |
| Lilly USA, LLC | $1,007.01 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $817.97 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $518.30 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $500.20 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $376.48 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $352.61 | 2020-2024 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $340.62 | 2019-2025 | Verquvo |
| Amgen INC. | $328.75 | 2020-2023 | Otezla, Repatha, Prolia |
| Novo Nordisk INC | $243.48 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $232.73 | 2021-2023 | Trintellix |
| Pfizer INC. | $226.80 | 2019-2024 | |
| Madrigal Pharmaceuticals | $189.42 | 2024-2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $151.74 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $125.37 | 2019-2025 | Spravato |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.